The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
about
Development of Novel Immunotherapies for Multiple MyelomaPatient-derived xenografts: a relevant preclinical model for drug developmentNovel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesHLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumorsBio-Orthogonal Mediated Nucleic Acid Transfection of Cells via Cell Surface Engineering.Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapyA Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor CellsT cells in multiple myeloma display features of exhaustion and senescence at the tumor site.Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research.Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.Supramolecular catalysis and dynamic assemblies for medicine.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Cancer Immunotherapy: Whence and Whither.Unravelling the biology of SCLC: implications for therapy.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.PBMC activation via the ERK and STAT signaling pathways enhances the anti-tumor activity of Staphylococcal enterotoxin A.In silico polypharmacology of natural products.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Emerging links among Chromosome Instability (CIN), cancer, and aging.Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinicThe role of dendritic cells in cancer.Heralding a new paradigm in 3D tumor modeling.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.Improved Targeting of Cancers with Nanotherapeutics.Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Delivery technologies for genome editing.Oncolytic viral therapy for pancreatic cancer.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelCurrent status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Molecular Dissection of CD8+ T-Cell Dysfunction.Continuous immunotypes describe human immune variation and predict diverse responses.Harnessing combined p19Arf and interferon-beta gene transfer as an inducer of immunogenic cell death and mediator of cancer immunotherapy.Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management.
P2860
Q28066890-5CDFF2D6-7CC7-41A6-965F-140098F7D88EQ28067191-97481124-D04B-47FD-880C-A2DE79C465E6Q28071998-1C41A7C5-DCBA-42B6-B0C0-0450DBC18C55Q28074619-8A289198-E1C7-427A-8659-3938532271BDQ33632104-B432AC7B-E521-4673-BD7D-091752A34DFCQ33645601-8012AA8F-A162-450C-8C23-D1DAC3C1DE26Q33731143-DB1413B4-F188-4C34-87EA-BAAB637DC738Q33881490-82E08E28-707D-45AB-B043-EDD2633FFA82Q37214957-FA2E4BDF-7AF3-4DED-912A-838C3BFDDA15Q37390723-20BDB74D-5378-4283-A6B4-61FDBC5B8DF5Q37417622-F9D891D9-755B-4B6C-873D-BE9549D0D954Q37743484-D14FD8F8-0CE1-4785-BCC1-F1979FDB38BDQ38636287-11CE9BEA-560C-4D10-A168-324971C814D8Q38676164-0756BB15-9336-4264-B714-D4A717EA7C1EQ38737924-67C1892E-0087-4E17-973B-F1742190DF39Q38769421-786572C6-669F-43A5-A765-695263682BCDQ38795442-A8A8166B-BFDE-47F9-BC1D-C9D88BE22A12Q38805787-F72220FD-2089-4466-A088-E3CA4D6A32F7Q38810969-35E44DAF-1D59-472D-903E-B44DB32683FBQ38873974-8DCD1C05-0141-41FE-B410-E9C3BDE78FADQ38929880-0BF5E7D2-B1EB-42C1-B36A-9566ED9A4E63Q38935027-9A0CF05D-B4BD-4137-8250-6EB601E03EA9Q38957065-21F1F43B-DC72-4FEC-9FEE-71D01E98EFEDQ38957511-57F261E7-698F-4365-B5EF-8EC6175A8AEBQ38979784-48C14FF3-21CC-4459-9716-FCD464FF66CAQ39045586-6BE9EAF3-91D6-49E6-8472-4B4FAAD09A68Q39069530-76B4B14B-7C2B-4784-8D61-DFD44D76C868Q39114835-CF817D53-873C-42AF-BA47-A606DDBA1C31Q39128240-35E7683B-3658-44D0-82EC-8C6A01F935E6Q39148961-8B50DF64-CB42-451F-A7A2-8D52C07A8BCDQ39168810-6E343366-8B51-4ADF-A849-FCFE23BF1B95Q39189908-DADC2E1A-78D5-42EB-8D92-DD839CFB5A51Q39197557-07FE2C65-5F6F-42A4-9F74-33EF44DEB6ACQ39240683-DCF12FBE-186A-4690-A14C-074AA14B6278Q39249589-EC14C5EC-BF96-466C-904C-A563CE62B0DEQ39280002-9535BC6B-278E-4B8F-97BF-55529137CC7BQ39405489-4A9C5303-F37A-41A8-8D54-4B5B35FE8708Q40139930-F286F962-6698-420A-A465-D7692C6834C4Q40206389-4BB5EE3F-A42B-4D83-85BF-8A6285C7F1A2Q40226483-87F17735-417D-4C6C-B521-FFB31F4860F3
P2860
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
@en
type
label
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
@en
prefLabel
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
@en
P2093
P2860
P1476
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
@en
P2093
Danny N Khalil
Eric L Smith
Jedd D Wolchok
Renier J Brentjens
P2860
P304
P356
10.1038/NRCLINONC.2016.25
P407
P577
2016-03-15T00:00:00Z